FGFR2 and cholangiocarcinoma: An additional open-label, phase 2 study enrolling 122 patients with advanced CCA with FGFR2 fusion or rearrangement with progression on prior gemcitabine-based chemotherapy found an ORR of 23.1% (95% CI 15.6–32.2) [69].